Safety and immunogenicity of a novel oral hexavalent rotavirus vaccine：a phase I clinical trial

• Váldodahkkit: Zhi-Wei Wu (Dahkki), Qing-Liang Li (Dahkki), Hai-Song Zhou (Dahkki), Kai Duan (Dahkki), Zhao Gao (Dahkki), Xin-Jiang Zhang (Dahkki), Zhi-Jun Jiang (Dahkki), Zhi-Yong Hao (Dahkki), Fei Jin (Dahkki), Xuan Bai (Dahkki), Qi Li (Dahkki), Ge-Lin Xu (Dahkki), Yu-Liang Zhao (Dahkki), Xiao-Ming Yang (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2021-07-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Background Rotavirus infections, prevalent in human populations, are caused mostly by group A viruses. Immunization against rotaviruses in infancy is currently the most effective and economical strategy to prevent rotavirus infection. This study evaluated the safety of a novel hexavalent rotavirus v...